Current status and perspectives regarding the therapeutic potential of resveratrol supplementation in Parkinson s disease

Background and Objective: Parkinson’s disease is a common chronic, progressive, incurable neurodegenerative disease. The cause of Parkinson s disease (PD) is unknown, but several mechanisms have been proposed, including oxidative stress and mitochondrial dysfunction. The most pronounced neuropathological feature is a loss of dopaminergic neurons in the substantia nigra pars compacta, which leads to a reduction in dopamine levels in the target region, the striatum. It is characterized by bradykinesia, rigidity, tremor, and postural instability. Resveratrol is a natural polyphenol with many biological functions such as anti-oxidative and neuroprotective properties. This review summarizes what is known regarding the effects of resveratrol supplementation on PD and the mechanisms involved. Search Method: Databases including MEDLINE, EMBASE and Web of Science were searched until May 31th, 2019. Findings: Pre-clinical studies have shown that resveratrol supplementation is an appropriate therapeutic approach for PD. Resveratrol had beneficial effects on PD through activation of the AMPactivated protein kinase (AMPK)-silent information regulator 1 (SIRT1)-autophagy pathway. Resveratrol displays potent antioxidant activities, anti-inflammatory activity in the in vivo and in vitro model of PD. Conclusion: Current evidence documented the therapeutic benefits of resveratrol supplementation in the treatment of PD. Clinical trials and more in vivo studies are required to evaluate the therapeutic effects of resveratrol supplementation in the treatment of PD.

Keywords:

Resveratrol , Parkinson’s disease , oxidative stress , autophagy